Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total value of $218,099.34. Following the completion of the sale, the chief operating officer now owns 69,383 shares of the company’s stock, valued at $6,654,523.53. This trade represents a 3.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christina Rossi also recently made the following trade(s):

• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total value of $216,257.40.

Blueprint Medicines Stock Performance

BPMC opened at $90.14 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The company has a market cap of $5.73 billion, a PE ratio of -42.72 and a beta of 0.59. The stock has a 50-day moving average of $92.48 and a 200-day moving average of $97.13. Blueprint Medicines Co. has a 52-week low of $72.24 and a 52-week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s quarterly revenue was up 126.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.20) earnings per share. As a group, equities research analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BPMC has been the subject of several research reports. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wells Fargo & Company cut their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Wedbush restated an “outperform” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Thursday, November 14th. Finally, UBS Group began coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $122.11.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Amalgamated Bank lifted its position in shares of Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 109 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after buying an additional 131 shares during the last quarter. EFG Asset Management North America Corp. lifted its holdings in shares of Blueprint Medicines by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after buying an additional 132 shares during the last quarter. Pallas Capital Advisors LLC boosted its position in shares of Blueprint Medicines by 3.2% in the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 176 shares during the period. Finally, Clarus Wealth Advisors grew its stake in shares of Blueprint Medicines by 8.6% in the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 206 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.